Table 1.
Patient demographics
| OTIVACTO® (n = 7443) | SPIRIT® (n = 1737)a | Pooled (n = 9180) | |
|---|---|---|---|
| Mean age at registration, years (SD) | 65.07 (9.33) | 66.51 (10.30) | 65.34 (9.54) |
| Time between initial diagnosis and baseline visit, years (SD) | 4.77 (5.76) | 5.23 (5.90) | 4.86 (5.79) |
| Male, n (%) | 5094 (68.44) | 990 (56.99) | 6084 (66.27) |
| Smoker, n (%) | 3080 (41.38) | 695 (40.01) | 3775 (41.12) |
| Ex-smoker | 3325 (44.67) | 691 (39.78) | 4016 (43.75) |
| Non-smoker | 1038 (13.95) | 350 (20.15) | 1388 (15.12) |
| Gold group, n (%) | |||
| A | 1625 (21.83) | 724 (41.68) | 2349 (25.59) |
| B | 3639 (48.89) | 595 (34.25) | 4234 (46.12) |
| C | 376 (5.05) | 241 (13.87) | 617 (6.72) |
| D | 1803 (24.22) | 176 (10.13) | 1979 (21.56) |
| Baseline pulmonary therapy, n (%)b,c | |||
| Short-acting β2-agonist | 1056 (14.19) | 318 (18.31) | 1374 (14.97) |
| Long-acting β2-agonist | 1100 (14.78) | 226 (13.01) | 1326 (14.44) |
| Short-acting anticholinergic | 513 (6.89) | 20 (1.15) | 533 (5.81) |
| Long-acting anticholinergic | 1999 (26.86) | 476 (27.40) | 2475 (26.96) |
| Long-acting anticholinergic + long-acting β2-agonist | 50 (0.67) | 42 (2.42) | 92 (1.00) |
| Short-acting anticholinergic + short-acting β2-agonist | 1071 (14.39) | 79 (4.55) | 1150 (12.53) |
| Long-acting β2-agonist + inhaled corticosteroid | 859 (11.54) | 156 (8.98) | 1015 (11.06) |
| Inhaled corticosteroids | 326 (4.38) | 93 (5.35) | 419 (4.56) |
| Systemic corticosteroids | 45 (0.60) | 23 (1.32) | 68 (0.74) |
| Theophylline | 719 (9.66) | 13 (0.75) | 732 (7.97) |
| Roflumilast | 36 (0.48) | 20 (1.15) | 56 (0.61) |
| Other | 192 (2.58) | 14 (0.81) | 206 (2.24) |
Patients were classified based on exacerbations and symptoms as outlined in GOLD 2017 [19]
GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation
aOne patient’s smoking status was missing from this group
bSome patients were included in multiple groups
cSome patient data were missing